Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Dec;32(12):2187-2188.
doi: 10.1111/exd.14731. Epub 2022 Dec 26.

"Superresponders" at biologic treatment for psoriasis: A comparative study among IL17 and IL23 inhibitors

Luca Mastorino  1 , Sara Susca  1 , Caterina Cariti  1 , Anna Verrone  1 , Elena Stroppiana  1 , Michela Ortoncelli  1 , Paolo Dapavo  1 , Simone Ribero  1 , Pietro Quaglino  1
Affiliations
Comment

"Superresponders" at biologic treatment for psoriasis: A comparative study among IL17 and IL23 inhibitors

Luca Mastorino et al. Exp Dermatol. 2023 Dec.
No abstract available

Keywords: IL17 inhibitors; Il23 inhibitors; PASI; biologics; psoriasis; superresponders.

PubMed Disclaimer

Comment on

References

REFERENCES

    1. Tsai YC, Tsai TF. Switching biologics in psoriasis - practical guidance and evidence to support. Expert Rev Clin Pharmacol. 2020;13(5):493-503. doi:10.1080/17512433.2020.1767590
    1. Torres T, Balato A, Conrad C, et al. Secukinumab drug survival in patients with psoriasis: a multicenter, real-world, retrospective study. J Am Acad Dermatol. 2019;81(1):273-275. doi:10.1016/j.jaad.2019.02.031
    1. Mastorino L, Roccuzzo G, Dapavo P, et al. Patients with psoriasis resistant to multiple biological therapies: characteristics and definition of a difficult-to-treat population. Br J Dermatol. 2022;187(2):263-265. doi:10.1111/bjd.21048
    1. Ruiz-Villaverde R, Vasquez-Chinchay F, Rodriguez-Fernandez-Freire L, C Armario-Hita J, Pérez-Gil A, Galán-Gutiérrez M. Super-responders in moderate-severe psoriasis under Guselkumab treatment: myths, realities and future perspectives. Life (Basel). 2022;12(9):1412. doi:10.3390/life12091412
    1. Eyerich K, Weisenseel P, Pinter A, et al. IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE). BMJ Open. 2021;11(9):e049822. Published 2021 Sep 13. doi:10.1136/bmjopen-2021-049822

Substances

LinkOut - more resources